22 Dec 2025 - Johns Hopkins Scientists Develop Therapy for T-Cell Cancers
- Suman Paul
- Dec 22, 2025
- 1 min read
We developed a new antibody-drug conjugate that precisely targets TRBC2-positive T-cell cancers (Jiaxin Ge et al., Nature Cancer 2025). This extends a precision strategy first shown in 2024 for TRBC1 tumors (Nichakawade et al., Nature 2024). The current study was led by graduate student, Jiaxin Ge along with multiple collaborators. The therapy selectively kills cancer cells while sparing enough normal T cells, addressing a major challenge in treating T-cell lymphomas and leukemias. Published in Nature Cancer, the work offers a long-awaited treatment option for about half of T-cell cancer patients who previously lacked a targeted therapy.